Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAYPRO vs SUPRENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Osteoarthritis,Rheumatoid arthritis
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
600 mg orally once daily; max 1200 mg/day
Adults: 200 mg orally twice daily with meals.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
>99% bound primarily to albumin.
Approximately 95-98% bound to plasma proteins, primarily albumin.
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Oral: approximately 80-90%.
Oral bioavailability is approximately 70-80%.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Not approved for pediatric use
Not recommended for patients under 18 years; safety and efficacy not established.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAYPRO vs SUPRENZA, answered by our medical review team.
DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAYPRO and SUPRENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAYPRO and SUPRENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.